Kornimate/medical-research-clean huggingface dataset:
detecting atrial fibrillation in patients with an embolic stroke of undetermined source (from the daf-esus registry)

Conditions: Fibrillation, Atrial

Summary: the presence of interatrial block (iab) is associated with the development of atrial fibrillation (af). the aim of this study was to determine whether p-wave duration and presence of iab before the implantation of a cardiac implantable electronic device (cied) are associated with the presence of atrial high rate episodes (ahre), during long-term follow-up.

the presence of interatrial block (iab) is associated with the development of atrial fibrillation (af). the aim of this study was to determine whether p-wave duration and presence of iab before the implantation of a cardiac implantable electronic device (cied) are associated with the presence of atrial high rate episodes (ahre), during long-term follow-up.

Eligibility criteria:
inclusion criteria: * patients in sinus rhythm * with or without previous paroxysmal af * with dual-chamber pacemakers (pms), implantable cardioverterdefibrillators (icds), and devices for cardiac resynchronization therapy (crt) * capable of atrial activity monitoring were included in the study exclusion criteria: -previous documented atrial fibrillation

Keywords: cardiac implantable electronic devices interatrial block p-wave duration
decreasing the incidence of post-operative nausea and vomiting (ponv) in bariatric patients

Conditions: Nausea; Vomiting

Summary: the study drug, aprepitant, is currently used to control chemotherapy induced nausea and vomiting and is also approved for post-operative nausea and vomiting. the investigators' evaluation of it in morbidly obese patients will demonstrate its ability to control nausea and vomiting post-operatively in this subset of patients.

the purpose of this study is to evaluate the effectiveness of aprepitant, also known as emend, in reducing post-operative nausea and vomiting in morbidly obese patients. post-operative nausea and vomiting that occurs in morbidly obese patients can greatly increase the chances of complications during the post-operative period. by treating morbidly obese patients with aprepitant, the goal is to reduce the risk of such complications that may be induced by nausea and vomiting.

Eligibility criteria:
inclusion criteria: subjects included in this study must be: * female * at least 18 years of age * non-smoking * at high risk for ponv * obese with a bmi of at least 45 kg/m2 * undergoing upper gastrointestinal surgery requiring postoperative opioid analgesia exclusion criteria: subjects will be excluded if: * they have a known allergy to aprepitant or ondansetron * they are currently taking orap (pimozide), seldane (terfenadine), hismanal (astemizole), or propulsid (cisapride) * they are pregnant * they are breastfeeding * they plan on getting pregnant in the 2 months following surgery * they are not able to receive patient controlled analgesia (pca) following surgery * they have a known drug or alcohol abuse problem * they have chronic nausea and vomiting

Keywords: post operative obese
bioimpedance variation of free flap for after clamping

Conditions: Thrombosis

Summary: monitrans project consist of developing a monitoring technology of post-operative breast reconstruction by detecting thrombosis. its aim is to reducing time spent in hospital by monitoring patients at home. thrombosis following to abdominal free flap harvesting for breast reconstruction is a rare phenomenon (with a 2 until 15 % frequency). moreover, it leads to ischemia by limiting water intake in the plasma compartments. the investigator would like to prove, by this research project, that they are able to detect ischemia via bioimpedance technology. during abdominal free flap harvesting for breast reconstruction, there are few minutes where the flap is clamped because of anastomosis on the recipient vessels. the investigators would seize the opportunity of this step, which is similar to vascular thrombosis, to measure bioimpedance variations. therefore they would like to measure variations of the flap bioimpedance before and after vascular section. another purpose consists of developing an algorithm which will detect postoperative thrombosis.


Eligibility criteria:
inclusion criteria: * patient suitable for a abdominal perforator based flap breast reconstruction * age over 18 years old exclusion criteria: * pregnancy * women with active pacemaker implant or artificial heart

Keywords: bioimpedance thrombosis free flap microsurgerie breast reconstruction
comparable investigation of one fraction radiotherapy and multifraction radiotherapy in patients with multiple myeloma.

Conditions: Multiple Myeloma and Malignant Plasma Cell Neoplasms

Summary: radiotherapy is required to overcome pain and to evoke recalcification in multiple myeloma (mm) patients. approximately 70% of all mm patients receive one or more radiotherapies in the course of their illness. the relief of pain is obtained in 75 - 100%. recalcification is achieved in 40 - 50% of the irradiated bone destructions.there were a lot of randomized trials showed the same effect of single (sf) and multiple fractions (mf) in pain relief and recalcification for patients with painful bone metastases from solid tumors. the role of different palliative radiotherapeutic regimens for mm is not well established due to lack of clinical trials. our prospective study analyzed the effect of two different radiotherapeutic regimens in the treatment of mm on pain relief, analgesics consumption and recalcification.

the primary aim of our prospective study is to analyzed the effect of two different radiotherapeutic regimens in the treatment of mm on pain relief, the secondary aim is to analyzed the effect of two different radiotherapeutic regimens in the analgesics consumption and recalcification. eligibility criteria are age more than 18 years, karnofsky index more than 40%, patients with painful bone destructions, patients with impending fracture in the region of destructions. exclusion criteria are: patients with bone metastases from solid tumors, patients with solitary plasmacytoma, patients who had received previous irradiation to the present painful destruction site, patients who were incapable to complete the quality of life questionnaires, patients with poor health status.

Eligibility criteria:
inclusion criteria: * karnofsky index more than 40% * patients with painful bone destructions. * patients with impending fracture in the region of destructions exclusion criteria: * patients with bone metastases from solid tumors * patients with solitary plasmacytoma * patients who had received previous irradiation to the present painful destruction site, * patients who were incapable to complete the quality of life questionnaires * patients with poor health status .
v114 and acute otitis media (v114-032/pneu-era)

Conditions: Acute Otitis Media (AOM)

Summary: the primary objective is to evaluate v114 in the prevention of vaccine-type acute otitis media (vt-aom) and the safety of v114 with respect to the proportion of participants with serious adverse events (saes) through completion of the study. the primary hypothesis is that v114 is superior to no v114 in preventing vt-aom as assessed by the incidence of vt-aom.


Eligibility criteria:
inclusion criteria: * is healthy (based on a review of medical history and physical examination) * is male or female, approximately 2 months of age, from 42 days to 90 days of age exclusion criteria: * was born prior to 37 weeks of gestation. * has a history of invasive pneumococcal disease (ipd) (positive blood culture, positive cerebrospinal fluid culture, or other sterile site) or known history of other culture positive pneumococcal disease. * has a known hypersensitivity to any component of the pneumococcal conjugate vaccine (pcv), any component of the licensed pediatric vaccines to be administered concomitantly in the study, or any diphtheria toxoid-containing vaccine. * has any contraindication to the concomitant study vaccines being administered in the study. * has external auditory canal atresia/stenosis. * has a known or suspected impairment of immunological function.
the interaction between metformin and microbiota - the memo study.

Conditions: Type 2 Diabetes Mellitus

Summary: metformin has been used in sweden since 1957, and it is recommended as first line therapy for type 2-diabetes (t2d) in national and international guidelines. however, adverse effects involving diarrhea, constipation, bloating, and abdominal pain are common which leads to discontinuation of medication or not being able to reach therapeutic doses. here the investigators will perform a prospective study to investigate whether i) participants with t2d who experience adverse events following metformin treatment have an altered microbiota at baseline compared to participants without adverse events and ii) if the microbiota is altered in participants during onset of adverse events. the investigators hypothesis is that adverse effects associated with metformin are caused by an altered gut microbiota, either at base line or following metformin treatment. the study design is a nested case-cohort study. the investigators will recruit 600 patients and expect 200 individuals to have side effects and 400 without during a 24-month study period. fecal samples will be collected at baseline, 2 months, and 4 months or when gastrointestinal symptoms occur. all fecal samples will be sequenced by 16s rrna (ribosomal ribonucleic acid) sequencing to obtain a baseline microbiota profile; a subpopulation consisting of homogenous groups of participants will be in depth-analyzed using shotgun sequencing. if the hypothesis is confirmed this project may lead to bacterial therapies that will allow more patients tolerate metformin.


Eligibility criteria:
inclusion criteria: * type 2 diabetes (diagnosis set within the last 12 months) * planned metformin treatment * age: 40 - 80 years * have provided written informed consent. exclusion criteria: * already started treatment with metformin * intestinal disease incl. irritable bowel syndrome * treatment with antibiotics in the last 3 months * inflammatory disorder t.ex. rheumatoid arthritis * anemia, haemoglobinopathy * alcohol or drug abuse * cancer disease under treatment

Keywords: metformin gastrointestinal side effects microbiota
the effect of traxi panniculus retractor on surgical time at non-emergent cesarean delivery in obese women

Conditions: Obesity

Summary: this is an unblinded, randomized control trial of obese women to evaluate the impact of the traxi panniculus retractor (tpr) on the cesarean operative time and surgical blood loss when compared to silk tape.

the purpose of the study is to assess whether using the traxi panniculus retractor during cesarean section, in obese (bmi greater than or equal to 30kg/m2 at time of delivery) women, can decrease the cesarean operative time compared to using silk tape to retract the panniculus. operative time is defined as the time from when the patient lies on the operating room table (at completion of the epidural/spinal anesthesia) until fascial closure.

Eligibility criteria:
inclusion criteria: * current bmi equal to or greater than 30 kg/m2 at last prenatal visit or on day of admission to l\&d * requires panniculus retractor for cesarean delivery, as determined by the surgeon * non-emergent cesarean delivery * spinal or epidural anesthesia * low transverse skin incision * gestational age equal to or more than 32 weeks 0 days * singleton pregnancy * three or less previous cesarean deliveries. * english speaking exclusion criteria: * use of alexis or any other retractor * general anesthesia * fetal demise * placenta previa * history of bariatric surgery * adhesive allergy
impact of smoking and nicotine on the risk of being infected with covid-19

Conditions: Smoking Behaviors

Summary: several studies have shown that smokers have a higher risk of developing a severe form of covid-19 once a person has been infected. this is explained by the damage caused by smoking at the bronchopulmonary level and an overexpression of some coronavirus receptors at the pulmonary level when exposed to tobacco. in contrast, recent data indicate that smokers are proportionally less infected with the covid-19 virus since all available cohort data from around the world show a very low rate of smokers among covid-19 infected subjects. the mechanisms at the origin of this protective effect are not known. all of these data lead us to question the real role of nicotine in the protective effect of tobacco observed in the general population against infection by the covid-19 virus. the objectives are : * to show that subjects taking nicotine substitutes as part of a smoking cessation program are less infected with covid-19 than non-smokers. * to show that active smokers are less infected with covid-19 than non-smokers. * to compare the percentage of positive serological tests in subjects taking nicotine substitutes to the percentage of positive serological tests in active smokers.


Eligibility criteria:
inclusion criteria: * age \> 18 years old * subject who will require a serological test for covid-19 virus as part of standard of care. * group 1: active smoker since october 2019 * group 2: smoker undergoing smoking cessation and taking nicotine substitutes on a regular basis since october 2019 * group 3: non-smoker exclusion criteria: * inpatient subject * subjects with a chronic serious pathology modifying the risk of exposure to covid-19
mid- and long-term evaluation of the results of patients undergoing spinal cord stimulation with microfractures + bst cargel in the treatment of patellofemoral chondral lesions of the knee

Conditions: Chondral Lesion of the Knee; Patellofemoral Disorder

Summary: the study consists of 3 phases (identification of eligible patients, follow-up by telephone or telemedicine platform and the collection of study-specific clinical data of enrolled patients): * identification by trained medical personnel of subjects who meet the study inclusion criteria. * once the patient's informed consent has been obtained, the study-specific questionnaires will be submitted. * clinical score data will be collected from the questionnaires conducted at mid- and long-term follow-up of patients enrolled in the study. the data collected during the long-term follow-up will be used to evaluate the time course of the results obtained after treatment of osteochondral lesions of the patellar cartilage by spinal cord stimulation with microfractures


Eligibility criteria:
inclusion criteria: * male or female patients, aged between 18 and 75 years; * bmi up to 30 kg/m2; * patients without subsequent surgery on the patellofemoral cartilage of the knee undergoing treatment; * ability and consent of patients to actively participate in the rehabilitation protocol and clinical and radiological follow-up; * signature of informed consent * availability * competent patients exclusion criteria: * patients no longer available; * patients who do not agree to undergo assessment; * deceased patients
respiratory muscle fatigue at different breathing modes

Conditions: Healthy

Summary: the study aims at investigating if time to respiratory muscle fatigue and metabolism are influenced by the pressure wave form mode applied during resistive breathing.

in healthy subjects fitted with a nasogastric double balloon catheter and breathing at a resistance, the investigators will measure time to failure, borg ratings, vo2, vco2, flow, esophageal-, gastric- and airway-pressure. this will be done during breathing at either a square wave or triangle wave pressure waveform, in random order and trials separated by \>two days. further respiratory muscle fatigue will be investigated pre and post intervention by maximal esophageal pressure generation (voluntary and with cervical magnetic stimulation).

Eligibility criteria:
inclusion criteria: * healthy men or women * age ≥18 and ≤60 years * bmi ≥ 20 and ≤30 exclusion criteria: * drug addiction defined as the use of cannabis, opioids or other drugs * previous and present neurologic (e.g. ataxia), musculoskeletal (e.g. muscular dystrophy) or mental illnesses (e.g. schizophrenia) * history of mechanical ventilation, covid-19 with respiratory complications, lung cancer * part of lung resected * presence of dyspepsia/heart-burn/abdominal pain * presence of esophageal varices * presence of liver disease * presence of esophageal hernia * pregnancy * failure to comply with transcranial magnetic stimulation adult safety screen * history of epilepsy, metal implants in head or jaw * acute or chronic lung diseases, e.g. asthma, copd, bronchitis etc. * lack of ability to cooperate
breast mri spectroscopy

Conditions: Suspicion of, or Known Breast Cancer

Summary: the purpose of this study is to provide physicians with additional information not available with standard imaging methods for breast disease. as part of the mri examination ordered by your physician, a new method of analyzing the images or pictures will be used. this new method is called spectroscopy and is used routinely on other parts of the body such as the prostate and brain. pictures produced with this sequence may look slightly different than the regular mri pictures. using spectroscopy data, it may be possible to distinguish benign conditions of the breast from malignant tumors and provide more precise information than can be obtained with regular mri.

our aim is to perform mr spectroscopy (mrs) on 150 evaluable patients at the end of their routine breast mri examination using a software package from general electric medical systems milwaukee, wi). this will add time to the routine examination but will not involve additional injections of contrast. we will analyze the spectroscopic data to determine if benign lesions can be reliably differentiated from malignant ones.

Eligibility criteria:
inclusion criteria: * scheduled for diagnostic breast mri examination or interventional procedure for a known or suspected breast lesion exclusion criteria: * patients who would be normally excluded from undergoing an mri examination: * patients with a pacemaker, aneurysm clip or any other condition that would warrant avoidance of a strong magnetic field

Keywords: breast cancer mri spectroscopy diagnostic radiology
a multicenter, double-blind, randomized, placebo-controlled, parallel group trial to investigate the efficacy and safety of spm 927 (200mg/day and 400mg/day) as adjunctive therapy in subjects with partial seizures with or without secondary generalization

Conditions: Partial Seizures With or Without Secondary Generalization

Summary: male and female patients between 16 and 70 years of age who are diagnosed with epilepsy with partial seizures and are taking up to 3 medications for this medical condition will take part in this research study at approximately 80 different locations in australia and europe. the purpose of this study is to evaluate the effectiveness, safety and tolerability of consistent dosages of study drug (lacosamide) taken orally twice a day for about 4 months. each patient who qualifies and chooses to participate in the study will receive placebo (inactive drug) or gradually increasing doses of lacosamide (spm 927) up to the target dose of 200mg/day or 400mg/day. the target dose or placebo will be maintained for 12 weeks. the study clinic visits will include a medical history and physical exam, ecg, blood and urine sample collection, and completion of a seizure diary. patients who complete the study may enroll in an extension trial and receive active study drug.


Eligibility criteria:
inclusion criteria: * partial seizures with or without secondary generalization exclusion criteria: * subjects received spm 927 in a previous trial
oral sweet solution to prevent pain during neonatal hip examination

Conditions: Pain

Summary: this study evaluates the pain relieving effect of oral glucose during hip examinations on healthy, fullterm infants.

all healthy, fullterm infants undergoes a medical examination after birth where 21 different components are assessed. one of the components is the hip examination which appears to be painful. since painful experiences early in life can cause longterm negative effects it is important to treat pain during painful procedures. one hundred healthy, fullterm infants were randomized to either glucose or sterile water orally before the routine medical examination before discharge from the maternity ward.

Eligibility criteria:
inclusion criteria: * healthy, fullterm infants that were undergoing a routine medical examination exclusion criteria: * prematurity * parents inability to speak swedish well enough to give consent * congenital malformations or other illnesses * any pain-relieving medicine administered in the previous 24 hours
non-alcoholic fatty liver disease (nafld) in hiv: the role of nutritional interventions

Conditions: HIV Infections; Fatty Liver

Summary: the purpose of this study is to evaluate the effect of a one-year nutritional intervention with either betaine or vitamin e supplementation, or a weight reducing diet and exercise program on liver steatosis and steatohepatitis.


Eligibility criteria:
inclusion criteria: * baseline liver biopsy with macrovesicular fatty degeneration with inflammation (lobular or portal), with or without mallory bodies, hepatocyte damage, and/or fibrosis diagnostic of nafld * convincing evidence of negligible alcohol consumption (\< 20 grams of ethanol per day) obtained from a detailed history, confirmed by at least one close relative * if hyperlipidemia or diabetes, stable drug regimen required for the 6 months prior to and during the study * willingness to maintain stable weight and normal exercise program for the duration of the study, if randomized to vitamin e or betaine exclusion criteria: * liver disease of other etiology diagnosed as per routine medical investigation (e.g., chronic viral hepatitis, auto-immune chronic hepatitis, primary biliary cirrhosis or genetic liver disease such as wilson's disease, hemochromatosis, alpha-1 antitrypsin deficiency, or biliary obstruction) * complications of liver disease such as recurrent variceal bleeding, resistant ascites, spontaneous portosystemic encephalopathy, or bacterial peritonitis * concurrent medical illness contra-indicating a liver biopsy, history of unexplained bleeding, hemophilia or abnormal coagulation results as per routine laboratory work-up or other reason judged by the hepatologist to contra-indicate a percutaneous liver biopsy * medications known to precipitate steatohepatitis (corticosteroids, high dose estrogens, methotrexate, amiodarone, calcium channel blockers, spironolactone, sulfasalazine, naproxen, oxacillin or ampinovire) in the 6 months prior to entry * antioxidant vitamin supplementation, ursodeoxycholic acid, or any other experimental drug 6 months prior to study entry * pregnant or lactating

Keywords: hiv non-alcoholic fatty liver disease